+

GR3032361T3 - Use of nuclear magnetic resonance to identify ligands to target biomolecules - Google Patents

Use of nuclear magnetic resonance to identify ligands to target biomolecules

Info

Publication number
GR3032361T3
GR3032361T3 GR20000400014T GR20000400014T GR3032361T3 GR 3032361 T3 GR3032361 T3 GR 3032361T3 GR 20000400014 T GR20000400014 T GR 20000400014T GR 20000400014 T GR20000400014 T GR 20000400014T GR 3032361 T3 GR3032361 T3 GR 3032361T3
Authority
GR
Greece
Prior art keywords
ligand
target molecule
magnetic resonance
nuclear magnetic
target biomolecules
Prior art date
Application number
GR20000400014T
Other languages
English (en)
Inventor
Stephen W Fesik
Philip J Hajduk
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24218250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3032361(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of GR3032361T3 publication Critical patent/GR3032361T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compounds Of Iron (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
GR20000400014T 1995-11-14 2000-01-14 Use of nuclear magnetic resonance to identify ligands to target biomolecules GR3032361T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/555,691 US5698401A (en) 1995-11-14 1995-11-14 Use of nuclear magnetic resonance to identify ligands to target biomolecules
PCT/US1996/018270 WO1997018471A1 (en) 1995-11-14 1996-11-13 Use of nuclear magnetic resonance to identify ligands to target biomolecules

Publications (1)

Publication Number Publication Date
GR3032361T3 true GR3032361T3 (en) 2000-04-27

Family

ID=24218250

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000400014T GR3032361T3 (en) 1995-11-14 2000-01-14 Use of nuclear magnetic resonance to identify ligands to target biomolecules

Country Status (13)

Country Link
US (2) US5698401A (el)
EP (2) EP0981049B1 (el)
JP (1) JP3032301B2 (el)
AT (2) ATE189063T1 (el)
AU (1) AU701810B2 (el)
CA (1) CA2237343C (el)
DE (2) DE69606324T3 (el)
DK (1) DK0866967T4 (el)
ES (1) ES2143793T5 (el)
GR (1) GR3032361T3 (el)
IL (2) IL155988A (el)
PT (1) PT866967E (el)
WO (1) WO1997018471A1 (el)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989827A (en) * 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
US6426058B1 (en) 1996-03-29 2002-07-30 The Regents Of The University Of California Enhancement of NMR and MRI in the presence of hyperpolarized noble gases
DE19649359C1 (de) * 1996-11-28 1998-02-12 Thomas Prof Dr Peters Verfahren zum Nachweis biologisch aktiver Substanzen in Substanzbibliotheken
US6043024A (en) * 1997-04-18 2000-03-28 Abbott Laboratories Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
AU772620B2 (en) * 1997-04-18 2004-05-06 Abbvie Inc. Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
US20030143757A1 (en) * 1997-06-13 2003-07-31 Jonathan Moore Methods for identifying drug cores
CA2292751A1 (en) * 1997-06-13 1998-12-17 Christopher A. Lepre Methods for identifying drug cores
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
AU766923B2 (en) * 1998-12-30 2003-10-23 Ge Healthcare Limited NMR spectroscopic in vitro assay using hyperpolarization
TWI283659B (en) * 1999-04-09 2007-07-11 Abbott Lab Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6897337B2 (en) * 1999-04-09 2005-05-24 Abbott Laboratories Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6333149B1 (en) * 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US6171804B1 (en) 1999-07-12 2001-01-09 The Rockefeller University Method of determining interdomain orientation and changes of interdomain orientation on ligation
AU6115300A (en) * 1999-07-19 2001-02-05 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
US7105310B1 (en) * 2000-07-19 2006-09-12 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
CA2383559A1 (en) * 1999-08-23 2001-03-01 Polaris Pharmaceuticals, Inc. Inhibitors of binding between proteins and macromolecular ligands
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
WO2001023330A2 (en) * 1999-09-29 2001-04-05 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
JP2003510608A (ja) * 1999-09-29 2003-03-18 スミスクライン・ビーチャム・コーポレイション 標的生体分子と相互作用する化合物を同定するための一次元および多次元核磁気共鳴の使用法
US6677160B1 (en) * 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
GB9925677D0 (en) * 1999-10-29 1999-12-29 Pharmacia & Upjohn Spa Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
BR0108606A (pt) * 2000-02-25 2003-01-07 Wyeth Corp Métodos de planejamento de droga com base na estrutura empregando-se em/rmn
WO2001079852A2 (en) * 2000-04-17 2001-10-25 Pharmacia & Upjohn Company Nmr-methods for indentifying sites in papillomavirus e2 protein
GB0013115D0 (en) * 2000-05-31 2000-07-19 Imp College Innovations Ltd Biological materials and methods for use in the prevention or treatment of infections
US7146277B2 (en) * 2000-06-13 2006-12-05 James H. Prestegard NMR assisted design of high affinity ligands for structurally uncharacterized proteins
US6652833B2 (en) 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
CA2423914C (en) 2000-09-27 2010-11-30 Universiteit Leiden Method for applying nmr for ligand discovery or as a drug screening tool
SE0003811D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Screening methods
AU2002256556A1 (en) * 2000-12-21 2002-07-01 Triad Therapeutics, Inc Sea-trosy and related methods
RU2274639C2 (ru) * 2000-12-22 2006-04-20 Орто-Макнейл Фармасьютикал, Инк. Производные замещенного триазолдиамина, фармацевтическая композиция на их основе и способ ее получения
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
US7645569B2 (en) * 2001-01-26 2010-01-12 Board Of Regents, The University Of Texas System NMR detection of foreign PAS domain ligands
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry
DE10119455B4 (de) * 2001-04-20 2010-12-16 Siemens Ag Verfahren zum Auswerten von Daten, die mittels der Magnetresonanztechnik erzeugt werden und spektroskopische Information beinhalten
AU2002312059B2 (en) 2001-05-25 2009-01-15 Duke University Modulators of pharmacological agents
WO2002097450A2 (en) * 2001-05-30 2002-12-05 Triad Therapeutics, Inc. Nuclear magnetic resonance-docking of compounds
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
US7653490B2 (en) * 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
DE10144661C2 (de) * 2001-09-11 2003-08-14 Forschungsverbund Berlin Ev Vorrichtung und Verfahren zur Zuordnung der NMR-Signale von Polypeptiden
US7179450B2 (en) * 2001-09-20 2007-02-20 Medi-Physics, Inc. Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
WO2003040400A2 (en) * 2001-11-06 2003-05-15 Message Pharmaceuticals, Inc. Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
DE10160177A1 (de) * 2001-12-07 2003-06-26 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden die an ein drug target binden mittels 1H,1H-Kernresonanzspektroskopie
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20030180797A1 (en) * 2002-03-20 2003-09-25 Lin Yu Identification of ligands for a receptor family and related methods
WO2003091700A2 (en) * 2002-03-26 2003-11-06 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
DE10221158A1 (de) * 2002-05-13 2004-02-19 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden, die an ein drug target binden, mittels heteronuklearer Kernresonanzspektroskopie
CA2488773A1 (en) * 2002-06-10 2003-12-18 Prospect Pharma Method for obtaining dynamic and structural data pertaining to proteins and protein/ligand complexes
WO2004024895A2 (en) * 2002-09-16 2004-03-25 Plexxikon, Inc. Crystal structure of pim-1 kinase
WO2006078228A1 (en) * 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20040132102A1 (en) * 2002-10-29 2004-07-08 Maurizio Pellecchia Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy
NO20025738D0 (no) 2002-11-29 2002-11-29 Amersham Health As Metode
JP2007524374A (ja) * 2003-02-28 2007-08-30 プレキシコン，インコーポレーテッド Ｐｙｋ２結晶構造および使用
EP1611425A4 (en) * 2003-03-13 2011-03-30 Triad Therapeutics Inc CORE MAGNETIC RESONANCE ARRANGEMENT OF CHEMICAL SUBSTANCES USING ADVANCED ANTENNA SENSORS
EP1623216A2 (en) * 2003-04-11 2006-02-08 SGX Pharmaceuticals, Inc. Compound libraries and methods for drug discovery
EP1617221A4 (en) * 2003-04-23 2006-08-02 Olympus Corp METHOD FOR SCREENING A SUBSTANCE CAPABLE OF BINDING TO A RECEIVER
JP2004331832A (ja) * 2003-05-08 2004-11-25 Ricoh Co Ltd Ｄｎａインク組成物とそれを用いた識別画像印刷体、及びインクジェット記録装置
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7255985B2 (en) * 2003-07-10 2007-08-14 Pfizer Italia S.R.L. Fluorine NMR spectroscopy for biochemical screening
WO2005028624A2 (en) * 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
WO2005037853A2 (en) * 2003-10-07 2005-04-28 Prospect Pharma Side chain deuterated amino acids and methods of use
JP4192078B2 (ja) * 2003-11-26 2008-12-03 株式会社日立製作所 核磁気共鳴方法
WO2005052620A1 (ja) * 2003-11-28 2005-06-09 Hitachi, Ltd. 核磁気共鳴法を用いた、標的タンパク質のアゴニストおよびアンタゴニストの同定方法、およびこの方法に用いるプログラム
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
WO2006033962A2 (en) 2004-09-20 2006-03-30 Wisconsin Alumni Research Foundation Nonlinear spectroscopic methods for identifying and characterizing molecular interactions
WO2006082963A1 (ja) * 2005-02-07 2006-08-10 Mitsubishi Chemical Corporation 標的分子とリガンドあるいはリガンド候補化合物との結合検出方法
WO2007105094A1 (en) 2006-03-14 2007-09-20 Universität Basel Method for the identification of new leads for drug candidates
US8933209B2 (en) 2006-04-26 2015-01-13 Abbvie Inc. Dep2 and its uses in major depressive disorder and other related disorders
US7760342B2 (en) 2007-12-21 2010-07-20 Wisconsin Alumni Research Foundation Multidimensional spectrometer
JPWO2012108297A1 (ja) * 2011-02-07 2014-07-03 国立大学法人神戸大学 Ｒａｓ部分ポリペプチド含有水溶液及びＲａｓ機能阻害剤のスクリーニング方法
DK2807187T3 (en) 2012-01-26 2017-09-11 Christopher J Soares PEPTIDE ANTAGONISTS OF THE CALCITONIN-CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE
IL305285A (en) 2015-08-11 2023-10-01 Arch Biopartners Inc DPEP-1 binding compositions and methods of use
CA3035561A1 (en) 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT65361A (en) * 1989-12-29 1994-05-02 Univ Technologies Int Method for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
US5164297A (en) * 1990-05-03 1992-11-17 Advanced Magnetics Inc. Solvent mediated relaxation assay system
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
JP3169610B2 (ja) * 1991-06-27 2001-05-28 ジーンラブズ テクノロジーズ，インコーポレイテッド Ｄｎａ結合分子の検出のためのスクリーニングアッセイ

Also Published As

Publication number Publication date
DE69606324T3 (de) 2008-02-07
AU7732896A (en) 1997-06-05
ES2143793T5 (es) 2008-03-01
US5698401A (en) 1997-12-16
IL155988A0 (en) 2003-12-23
IL155988A (en) 2005-07-25
AU701810B2 (en) 1999-02-04
DE69606324T2 (de) 2000-07-06
JP3032301B2 (ja) 2000-04-17
EP0866967B1 (en) 2000-01-19
CA2237343A1 (en) 1997-05-22
DE69606324D1 (de) 2000-02-24
WO1997018471A1 (en) 1997-05-22
ES2143793T3 (es) 2000-05-16
IL123923A (en) 2005-07-25
DE69631842D1 (de) 2004-04-15
US5804390A (en) 1998-09-08
PT866967E (pt) 2000-04-28
EP0866967A1 (en) 1998-09-30
MX9803810A (es) 1998-09-30
ATE261581T1 (de) 2004-03-15
DK0866967T4 (da) 2007-12-10
EP0866967B2 (en) 2007-08-08
ATE189063T1 (de) 2000-02-15
EP0981049A1 (en) 2000-02-23
JPH11513498A (ja) 1999-11-16
DK0866967T3 (da) 2000-06-26
EP0981049B1 (en) 2004-03-10
CA2237343C (en) 2009-01-20

Similar Documents

Publication Publication Date Title
GR3032361T3 (en) Use of nuclear magnetic resonance to identify ligands to target biomolecules
GR3036454T3 (en) Use of nuclear magnetic resonance to design ligands to target biomolecules
CA2653517A1 (en) Process of designing a drug
WO1990010709A3 (en) Monoclonal antibodies for metallic cations on small molecules
FR2649526B1 (fr) Procede de fabrication de tetes magnetiques planaires par alveolage d'une plaquette non magnetique, et tetes magnetiques obtenues par un tel procede
EP1018365A8 (en) Coded particles for process sequence tracking in combinatorial compound library preparation
FR2710253B1 (fr) Système magnétique pour tomographie par résonance magnétique nucléaire.
AU7484694A (en) Method for magnetic resonance spectroscopic imaging with multiple spin-echoes
CA2235269A1 (en) Monoclonal antibody br110 and uses thereof
NO995078L (no) Anvendelse av endimensjonal kjernemagnetiskresonans for å identifisere ligander for å sikte inn biomolekyler
DE59007200D1 (de) Verfahren zur Bestimmung eines Analyten.
AU1406195A (en) Metal ion-ligand coordination complexes, antibodies directed thereto, and assays using such antibodies
EP0638816A3 (en) Measurement of the flow by a difference method of the complex image values by means of magnetic resonance.
DE3852906D1 (de) Dipyridoxyl-Phosphat als magnetisches Kernresonanz-Bildgebungsmittel.
DE69025351D1 (de) Durch Ätzen hergestellte Gradientenspule in Z-Achsenrichtung, für ein magnetisches Kernresonanz-System
AU8950291A (en) Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
DE59700179D1 (de) Magnetanordnung für die bildgebende magnetische Resonanz mit zwei getrennten Abbildungsvolumina
Juarez-Garcia et al. Combined Moessbauer and EPR studies of the S= 3 state of an exchange-coupled iron (III)-copper (II) complex: test for quantitative EPR analysis of integer spin systems
DE69100611D1 (de) Kompakte Sonde für die magnetische Kernresonanz.
FR2697930B1 (fr) Procédé de réalisation d'une image de référence synthétisée pour l'inspection d'objets.
FR2649213B1 (fr) Procede d'imagerie tridimensionnelle par resonance magnetique nucleaire
FR2669137B1 (fr) Procede de reconnaissance d'objets tridimensionnels par analyse d'image.
FR2693813B1 (fr) Procédé de réalisation d'une image de référence synthétisée à partir de données contenues dans une base de données CAO.
FR2704322B1 (fr) Système de bobines de gradient transverse pour appareil de résonance magnétique nucléaire.
JPS6488783A (en) Three-dimensional reprojecting device
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载